Evaluation of Epigallocatechin-3-Gallate as a Radioprotective Agent During Radiotherapy of Lung Cancer Patients: A 5-Year Survival Analysis of a Phase 2 Study

Evaluation of Epigallocatechin-3-Gallate as a Radioprotective Agent During Radiotherapy of Lung Cancer Patients: A 5-Year Survival Analysis of a Phase 2 Study

BackgroundPrevious analysis of the study (NCT02577393) had demonstrated the application of epigallocatechin-3-gallate (EGCG) could be safe and effective in the prevention and treatment of acute radiation esophagitis in patients with advanced lung cancer. EGCG seemed to improve the response rate of s...

Full description

Bibliographic Details
Main Authors: Wanqi Zhu, Yalan Zhao, Shuyu Zhang, Xiaolin Li, Ligang Xing, Hanxi Zhao, Jinming Yu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Oncology
Subjects:
Epigallocatechin-3-gallate
lung cancer
radiation-induced esophagitis
radioprotective agent
long-term follow-up
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.686950/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.686950/full

Similar Items